BR112022004573A2 - Método para identificar respondedores para degradadores de smarca2/4 - Google Patents

Método para identificar respondedores para degradadores de smarca2/4

Info

Publication number
BR112022004573A2
BR112022004573A2 BR112022004573A BR112022004573A BR112022004573A2 BR 112022004573 A2 BR112022004573 A2 BR 112022004573A2 BR 112022004573 A BR112022004573 A BR 112022004573A BR 112022004573 A BR112022004573 A BR 112022004573A BR 112022004573 A2 BR112022004573 A2 BR 112022004573A2
Authority
BR
Brazil
Prior art keywords
degraders
smarca2
mark2
identify responders
present
Prior art date
Application number
BR112022004573A
Other languages
English (en)
Inventor
Khare Satyam Leena
Muralidhara Ramachandra
Sanjita Sasmal
Susanta Samajdar
Original Assignee
Aurigene Discovery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Tech Ltd filed Critical Aurigene Discovery Tech Ltd
Publication of BR112022004573A2 publication Critical patent/BR112022004573A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

método para identificar respondedores para degradadores de smarca2/4. a presente invenção se refere a um método para tratar uma doença ou distúrbio com pelo menos um degradador de smarca2/4 em um sujeito que é respondedor a tal tratamento com base na presença das alterações específicas de tumor descritas no presente documento. a presente invenção também fornece os métodos para tratar câncer de próstata nos sujeitos que têm a probabilidade de responder ao tratamento com degradadores de smarca2/4.
BR112022004573A 2019-09-12 2020-09-11 Método para identificar respondedores para degradadores de smarca2/4 BR112022004573A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201941036639 2019-09-12
PCT/IB2020/058449 WO2021048799A1 (en) 2019-09-12 2020-09-11 Method for identifying responders to smarca2/4 degraders

Publications (1)

Publication Number Publication Date
BR112022004573A2 true BR112022004573A2 (pt) 2022-06-07

Family

ID=72840577

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004573A BR112022004573A2 (pt) 2019-09-12 2020-09-11 Método para identificar respondedores para degradadores de smarca2/4

Country Status (11)

Country Link
US (2) US11865114B2 (pt)
EP (1) EP4028557A1 (pt)
JP (1) JP2022547530A (pt)
KR (1) KR20220061974A (pt)
CN (1) CN114375192A (pt)
AU (1) AU2020345178A1 (pt)
BR (1) BR112022004573A2 (pt)
CA (1) CA3150354A1 (pt)
IL (1) IL291252A (pt)
MX (1) MX2022002244A (pt)
WO (1) WO2021048799A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202104495YA (en) * 2018-04-26 2021-05-28 Aurigene Discovery Tech Ltd Pyridazine derivatives as smarca2/4 degraders
CN114599428A (zh) * 2019-10-28 2022-06-07 豪夫迈·罗氏有限公司 双功能化合物
IL305956A (en) * 2021-03-31 2023-11-01 Duke Street Bio Ltd Pharmaceutical material
CN115611881A (zh) * 2021-07-13 2023-01-17 复旦大学 一种合成新型vhl配体4-f-vh032的方法
KR20240046498A (ko) 2021-08-09 2024-04-09 제넨테크, 인크. Brm의 조절에 사용하기 위한 페놀 유도체
WO2023022218A1 (ja) * 2021-08-20 2023-02-23 学校法人獨協学園獨協医科大学 線維腺腫と葉状腫瘍の鑑別方法
WO2023129506A1 (en) * 2021-12-28 2023-07-06 Board Of Regents, The University Of Texas System Potent and selective smarca2 degrading chimeric molecules as cancer therapeutics
WO2024002375A1 (zh) * 2022-06-30 2024-01-04 甘李药业股份有限公司 一种用作smarca2/4抑制剂的化合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3062106B1 (en) 2008-04-16 2020-11-11 The Johns Hopkins University Method for determining androgen receptor variants in prostate cancer
US8133724B2 (en) 2008-09-17 2012-03-13 University Of Maryland, Baltimore Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
CA2791244A1 (en) 2010-03-08 2011-09-15 Regents Of The University Of Minnesota Androgen receptor isoforms and methods
WO2014150751A2 (en) * 2013-03-15 2014-09-25 Novartis Ag Biomarkers associated with brm inhibition
JPWO2015005473A1 (ja) * 2013-07-12 2017-03-02 国立研究開発法人国立がん研究センター がんの治療への応答性を予測する方法
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
KR20190140438A (ko) 2017-02-28 2019-12-19 에피자임, 인코포레이티드 암 치료를 위한 smarca2의 저해
GB201714827D0 (en) 2017-09-14 2017-11-01 Nuclera Nucleics Ltd Novel use
SG11202104495YA (en) * 2018-04-26 2021-05-28 Aurigene Discovery Tech Ltd Pyridazine derivatives as smarca2/4 degraders

Also Published As

Publication number Publication date
JP2022547530A (ja) 2022-11-14
CA3150354A1 (en) 2021-03-18
CN114375192A (zh) 2022-04-19
US20210077486A1 (en) 2021-03-18
MX2022002244A (es) 2022-03-22
AU2020345178A1 (en) 2022-03-03
US20240156814A1 (en) 2024-05-16
EP4028557A1 (en) 2022-07-20
US11865114B2 (en) 2024-01-09
WO2021048799A1 (en) 2021-03-18
KR20220061974A (ko) 2022-05-13
IL291252A (en) 2022-05-01

Similar Documents

Publication Publication Date Title
BR112022004573A2 (pt) Método para identificar respondedores para degradadores de smarca2/4
Ghadjar et al. Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: first results of the randomized trial SAKK 09/10.
BR112018071683A2 (pt) método para tratar um câncer de mama, método para tratamento de um tumor em um paciente, método para tratar um indivíduo sofrendo com câncer por imunoterapia, método para induzir/melhorar uma resposta imune em um indivíduo, método para melhorar a vacina obi-822 induzida pela resposta imune em um indivíduo necessitando da mesma, método para identificar um paciente adequado para terapia do câncer e método para determinar o prognóstico do tratamento do câncer ou resposta do fármaco de um paciente
BR112017020973A2 (pt) método para tratar câncer em um paciente
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
BR112017025120A2 (pt) métodos de diagnóstico para terapia de células t
BR112012012610A2 (pt) terapia de combinação para o tratamento de câncer e ensaios diagnósticos para o uso na mesma
BR112017001420A2 (pt) método
BR112014030750A2 (pt) Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
BR112015012731A2 (pt) uso de eribulina no tratamento de câncer de mama
BR112016018205A2 (pt) métodos de tratamento de mal de alzheimer
BR112019027133B8 (pt) Uso de uma célula imune modificada deficiente para suv39h1
BR112018007671A2 (pt) terapia de combinação para tratamento de malignidades
MX2019003569A (es) Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos.
CO2022007361A2 (es) Terapia de combinación para el tratamiento de cáncer cerebral
BR112017022653A2 (pt) ?métodos para o tratamento ou para a prevenção de uma doença, da artrite reumatoide, da prostatite e da bph?
BR112022002098A2 (pt) Biomarcadores para determinar a eficácia de inibidores da via de sinalização imune
BR112018076528A2 (pt) composições e métodos para diagnosticar cânceres de pulmão usando perfis de expressão gênica
BR112019009771A2 (pt) ligação de anticorpos especificamente à cd66c e utilização dos mesmos
MX2017013390A (es) Método para el tratamiento de cáncer pulmonar.
BR112021023173A2 (pt) Moléculas de ligação à claudin-6 e usos das mesmas
BR112022007595A2 (pt) Métodos para tratar doença de alzheimer
CO2021005207A2 (es) Métodos de tratamiento
BR112018009528A2 (pt) método para determinar o risco de recorrência de um câncer de mama de um sujeito, método para prever a capacidade de resposta a uma terapia de um câncer de mama de um sujeito, métodos ou tratamentos de um sujeito que tem câncer de mama que não foi tratado ou foi tratado com quimioterapia por 5 anos, métodos para recomendar o tratamento para um sujeito que tem câncer de mama, método para tratar um sujeito que tem câncer de mama
BR112015031950A2 (pt) métodos para tratamento de câncer de ovário